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Abstract
Naloxone is a well-established essential medicine for the treatment of life-threatening heroin/opioid overdose in emergency 
medicine. Over two decades, the concept of ‘take-home naloxone’ has evolved, comprising pre-provision of an emergency sup-
ply to laypersons likely to witness an opioid overdose (e.g. peers and family members of people who use opioids as well as non-
medical personnel), with the recommendation to administer the naloxone to the overdose victim as interim care while awaiting 
an ambulance. There is an urgent need for more widespread naloxone access considering the growing problem of opioid overdose 
deaths, accounting for more than 100,000 deaths worldwide annually. Rises in mortality are particularly sharp in North America, 
where the ongoing prescription opioid problem is now overlaid with a rapid growth in overdose deaths from heroin and illicit 
fentanyl. Using opioids alone is dangerous, and the mortality risk is clustered at certain times and contexts, including on prison 
release and discharge from hospital and residential care. The provision of take-home naloxone has required the introduction of 
new legislation and new naloxone products. These include pre-filled syringes and auto-injectors and, crucially, new concentrated 
nasal sprays (four formulations recently approved in different countries) with speed of onset comparable to intramuscular naloxone 
and relative bioavailability of approximately 40–50%. Choosing the right naloxone dose in the fentanyl era is a matter of ongo-
ing debate, but the safety margin of the approved nasal sprays is superior to improvised nasal kits. New legislation in different 
countries permits over-the-counter sales or other prescription-free methods of provision. However, access remains uneven with 
take-home naloxone still not provided in many countries and communities, and with ongoing barriers contributing to imple-
mentation inertia. Take-home naloxone is an important component of the response to the global overdose problem, but greater 
commitment to implementation will be essential, alongside improved affordable products, if a greater impact is to be achieved.
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 * John Strang 
 john.strang@kcl.ac.uk
1 King’s College London, National Addiction Centre, 
Institute of Psychiatry, Psychology and Neuroscience, 
Addiction Sciences Building,4 Windsor Walk,Denmark Hill, 
London SE5 8BB, UK
2 South London and Maudsley NHS Foundation Trust, 
London, UK
3 National Drug and Alcohol Research Centre, University 
of New South Wales, Sydney, NSW, Australia
4 Monash Addiction Research Centre, Monash University, 
Melbourne, VIC, Australia
5 Department of Circulation and Medical Imaging, Norwegian 
University of Science and Technology, Trondheim, Norway
6 St. Olav’s Hospital, University Hospital of Trondheim, 
Trondheim, Norway
Key Points 
Take-home naloxone is an effective public health inter-
vention to prevent deaths and organ damage from opioid 
overdose.
Four naloxone nasal spray products that have been 
developed for layperson use are now approved, all 
with approximately 40–50% bioavailability relative to 
parenteral references. They are increasingly available in 
clinical practice in a growing number of countries
Ongoing implementation challenges include naloxone 
cost as well as politico-social (e.g. stigma) and legal bar-
riers (e.g. prescription status), although prescription-free 
distribution is now permitted in several countries (e.g. 
Australia, Canada, Italy, the UK).
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1 Introduction
With an increasing global problem of opioid use and depend-
ence, the mortality rate from opioid overdose continues to 
rise, and there are more than 100,000 deaths globally per 
annum [1]. Heroin is the most common drug involved in 
opioid overdose in much of the world, although prescription 
drugs and illicitly manufactured fentanyl (IMF) and analogues 
are increasingly implicated, particularly in North America. In 
the USA, 20,000 deaths from prescription opioids and 13,000 
deaths from heroin were registered in 2015 alone [2].
These deaths occur primarily in the community and, while 
sometimes the patient is alone, he/she often in the presence of 
others (especially with heroin overdose) [3–6]. As such, these 
deaths are potentially preventable with timely detection and 
administration of naloxone, along with wider resuscitation 
measures, by non-medical members of the general public.
Naloxone is a remarkable antidote that is opioid specific 
and actively displaces heroin and other opioids from the mu-
opioid receptor (MOR). It is a long-established medicine that 
is essential in the hospital emergency department and the 
ambulance medication kit. Naloxone administration reverses 
heroin/opioid overdose within minutes with rapid re-estab-
lishment of independent breathing and return of conscious-
ness (and, in individuals who are dependent on opioids, risk 
of precipitation of an opioid withdrawal syndrome).
‘Take-home naloxone’ (THN) for the reversal of heroin/
opioid overdose involves the pre-provision of an emergency 
naloxone kit, to non-medical persons along with training in 
basic overdose management, naloxone administration and 
after-care. The concept of THN constitutes an example of 
technology transfer, in that it tells us to take the solution 
(emergency naloxone kit) from the hospital into the com-
munity where the emergency (overdose) occurs, with the 
aim to reduce any harm (i.e. potential death) that could occur 
during the time delay while awaiting the arrival of an ambu-
lance. This follows the example of technology transfer for 
other medical emergencies, such as diabetic coma or severe 
anaphylactic reactions, where potentially life-saving medi-
cines (adrenalin/epinephrine, glucagon, snake anti-venom) 
are also pre-provided to the at-risk patient or individual, 
along with instructions to family members.
‘Take-home naloxone’ may be provided as part of compre-
hensive clinical care of patients in treatment for opioid use 
disorder in primary or specialty care or through dedicated 
THN schemes. Researchers have found that both peers and 
family members are highly willing to act as first responders 
providing interim emergency care whilst awaiting the arrival 
of ambulance (or other emergency medical care) [7, 8].
Support for THN has increased greatly in recent years, 
including guidelines from the World Health Organization [9] 
and endorsement from the United Nations [10], as well as from 
various national governments. Nevertheless, intervention iner-
tia around THN continues to exist, with countries, services 
and clinicians uncertain what they can, or cannot, provide. In 
the meantime, lives continue to be lost, including in situations 
where the overdose victim was still alive at the point of discov-
ery (and therefore death was likely preventable).
In this review, we provide the reader with the evidence 
for THN as a public health response to opioid overdose as 
well as presenting evidence on naloxone’s properties and 
the recent development of novel naloxone formulations and 
devices for layperson use as well as exploring ongoing chal-
lenges for implementation. To achieve a balanced reflection 
of the wider developments in the field of THN, we have 
deliberately brought together a team of co-authors with dif-
ferent areas of expertise who have led on the sections of 
this review. This paper draws on peer-reviewed and grey 
literature identified through a desk-based review of THN 
and naloxone formulations. English-language peer-reviewed 
literature was identified through searches of MEDLINE, 
EMBASE (via the OVID platform) and PubMed. Given the 
wide scope of this review, search terms included opioids, 
opiates, overdose, mortality, prevention, naloxone, intranasal 
(IN) and nasal. This general search strategy was then adapted 
by our co-authors to meet the specific focus of their respec-
tive section(s). Key literature (including grey literature) cited 
within the retrieved material was also consulted, and as a 
general principle, more recent literature was preferred over 
older data (1960–2009). Data from published papers and 
reports were extracted and synthesised as narrative reviews. 
We also refer the interested reader to earlier reviews with a 
more limited focus, including THN programmes [11, 12] 
and naloxone delivery systems [13, 14].
1.1  Structure
Sections 2 and 3 discuss the prevalence of opioid mortality 
and situational risk factors for overdose. Section 4 describes 
the discovery of naloxone and history of its use in medical 
practice as background for Sect. 5, which covers the study 
of pharmacokinetics and development of non-injectable 
formulations of naloxone. This is followed by a discussion 
of the pharmacodynamics of naloxone and its efficacy and 
safety for the emergency management of opioid overdose 
in Sect. 6. In Sects. 7 and 8, we review the effectiveness of 
THN and ongoing implementation barriers, leading up to 
concluding remarks in Sect. 9.
2  Epidemiology of Opioid Overdose Deaths
To understand the levels and variations in opioid overdose 
deaths, it is important to understand one of the important 
drivers in high-income countries, namely, prescription 
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opioid utilisation [15]. North America, Oceania and some 
western European countries account for more than 95% of 
the worldwide consumption of analgesic opioids [15], as 
illustrated in Fig. 1, despite accounting for only about 15% 
of the world’s population [15].
2.1  USA
2.1.1  Increasing Opioid Prescribing
The USA had a substantial increase in opioid prescribing for 
chronic non-cancer pain [16], with opioid analgesic use in 
North America rising from about 2.4 billion DDD (defined 
daily dose; i.e. “the assumed average maintenance dose per 
day for a drug used for its main indication in adults”)1 per 
annum in 2001–2003 to about 5.3 billion DDD per annum 
in 2011–2013 [15].
In recent years, a number of policies have been introduced 
to reduce the problem of excessive opioid prescribing [17]. 
These have included educating professionals and the general 
public about appropriate prescription opioid use, implemen-
tation of prescription drug monitoring programmes, attempts 
to reduce egregious prescribing (by so-called “pill mills”—
clinics devoted entirely to opioid prescribing) and develop-
ing novel abuse-deterrent opioid formulations. Despite an 
overall reduction in per capita prescribing since 2010, the 
oral morphine equivalent amount prescribed in 2015 was 
still approximately three times as high as in 1999 [18]. The 
unintended consequences of these supply-side interventions 
need to be considered. With access reduced and demand 
still high, individuals began to turn to the black market [19].
2.1.2  Increasing Opioid‑Related Overdoses
The rise in opioid analgesic use in the USA has been associ-
ated with substantial increases in non-fatal and fatal over-
dose. Since 2000, there has been a steady increase in the rate 
of opioid overdose deaths (see Fig. 2). From 1999 to 2015, 
more than 183,000 people died from overdoses related to 
prescription opioids. In 2016 alone, there were over 63,000 
drug-related deaths, of which 66% involved opioids (either 
prescription or illicit). In fact, the escalation in opioid over-
dose deaths has been a significant factor in reduced US life 
expectancy in 2015 and 2016, particularly for white Ameri-
cans [20].
2.1.3  Re‑emergence and Increase of Heroin Use
Despite concerted public health efforts to reduce opioid 
prescribing (see above), opioid-related deaths continued to 
increase by 16% from 2014 to 2015 [18]. These significant 
increases in mortality were largely driven by opioids other 
than methadone, predominantly IMF (see below) and heroin 
[21].
Fig. 1  Mean availability of opioids for pain management in 2011–2013 (Source: [15]). S-DDD defined daily doses for statistical purposes
1 https ://www.whocc .no/ddd/defin ition _and_gener al_consi dera/.
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A population-based study reported that the prevalence 
of heroin use increased from 0.3% in 2001–2002 to 1.6% 
in 2012–2013 [22], and heroin-related overdose increased 
from 1842 deaths in 2000 to 10,574 deaths in 2014 [17] 
(see Fig. 2). The increased availability of high-purity heroin 
combined with its low price (compared with diverted pre-
scription opioids) have been major drivers of the upward 
trends in heroin use and overdose deaths [21]. Nonmedical 
use of prescription opioids is considered a significant risk 
factor for heroin use [17].
2.1.4  Increasing Availability of Potent Illicit Opioids
In recent years, deaths from illicit synthetic opioids have 
outstripped deaths due to heroin and prescribed opioids in 
the USA. In 2015, the Drug Enforcement Administration and 
Centers for Disease Control and Prevention issued nation-
wide alerts identifying IMF as a threat [23].
Illicitly manufactured fentanyl and its analogues are sig-
nificantly more potent than morphine: carfentanil, for exam-
ple, is approximately 10,000 times more potent, gram for 
gram. Fentanyl is more likely to lead to overdose than other 
opioids and is thought to have reduced cross-tolerance to 
other opioids [24]. A much smaller dose of fentanyl than 
heroin is required to achieve the same drug effect: thus 
errors at the level of the illicit manufacture and distribu-
tion, as well as errors at the level of the end user, result in 
frequent accidental errors of dosage whose implications are 
far more profound than errors where the dose alteration is 
less severe [24]. The high potency of fentanyl makes it often 
both cheaper and easier to trade (and access) than heroin 
given its much smaller bulk [19, 25]. Illicitly manufactured 
fentanyl is also increasingly found as adulterant in non-opi-
oid drugs (e.g. cocaine) and considered a key factor for the 
more recent increases in opioid overdose mortality [21, 25, 
26] (see Fig. 2).
In Massachusetts (2014–2016), 36% of fentanyl deaths 
had evidence of an overdose occurring within seconds to 
minutes after drug use, and 90% of fentanyl overdose dece-
dents were pulseless upon emergency medical services 
(EMS) arrival [27]. It has been speculated whether massive 
overdoses are able to benefit from naloxone at all [28].
Fentanyl and its analogues differ from many other opioids 
by their propensity to induce muscle rigidity [29], including 
chest wall rigidity (sometimes called ‘wooden chest syn-
drome’), which makes assisted ventilation and breathing 
difficult [24] and may increase mortality risk and lead to 
rapid death [30]. Notably, muscle rigidity can be reversed 
by naloxone [30, 31]. Therefore, the same principles of 
response with THN initiatives apply to the prevention of 
deaths from fentanyl overdose, although early administration 
of naloxone is likely crucial.
2.2  Canada
Canada has the second highest level of prescribed opioid 
use globally after the USA, and consumption is increasing 
faster than in the USA, with a 203% increase from the 2-year 
period of 2000–2002 (8713 defined daily doses for statisti-
cal purposes2) to 2008–2010 (26,380 defined daily doses 
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Fig. 2  Overdose deaths involving opioids by type of opioid, USA, 2000–2016 (Source: US Centers for Disease Control and Prevention)
2 https ://www.incb.org/incb/en/narco tic-drugs /Avail abili ty/avail abili 
ty.html.
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for statistical purposes) [15]. From 1991 to 2004, annual 
prescriptions for opioids increased from 458 to 591 per 
1000 individuals [32], with opioid-related deaths doubling, 
from 13.7 to 27.2 per million in 2004. There are also recent 
indications of the use of IMF and analogues and associated 
overdoses [33], localised to certain provinces, such as Brit-
ish Columbia and Alberta [33].
2.3  Europe
Although pharmaceutical opioid use is increasing gradually 
in Western Europe, the prevalence is four times lower than 
in North America [34]. In general, heroin remains the most 
prevalent illicit opioid in Europe. However, in some countries, 
such as Estonia and Finland, where the heroin market plum-
meted in the early 2000s, heroin has been entirely displaced by 
fentanyl (mostly illicit) and buprenorphine, respectively [35].
In 2015, there were 8440 drug overdose deaths (any sub-
stance; occurring most commonly in the UK, followed by 
Germany and Sweden) in the European Union (plus Turkey 
and Norway), a total that continues to rise [36]. Most drug-
related deaths (79%) involved opioids, predominantly heroin, 
though potent synthetic opioids such as fentanyl and its newer 
derivatives seem to play an increasing role [37]. For example, 
in Estonia there was a spike in overdose deaths in 2012 that 
was mainly attributable to fentanyl. On the European bound-
ary, there have also been reports of fentanyl use in parts of 
Russia owing to heroin shortages. Of the 9263 drug-related 
deaths reported in Russia in 2010, 6324 were attributed to 
opioid use [38]. (N.B.: Comparisons across different countries 
are hampered by differences in data collection [39]).
2.4  Australia
In Australia, annual opioid analgesic use increased from 
23 million DDD in 2001–2003 to 106 million DDD in 
2011–2013 [15]. In 2016, there were 1045 opioid-related 
deaths in Australia, accounting for approximately 75% of 
all drug-related deaths [40]. Whilst the rate of heroin-related 
deaths has remained stable, overdose deaths from prescrip-
tion opioids are now more common, having increased by 
127% from 2006 to 2016 [40]. Deaths related to synthetic 
opioids (fentanyl, tramadol and pethidine, excluding metha-
done) have also been increasing, from approximately 5% 
(1999) to 17% (2016) of opioid-related deaths [40].
3  Clusters of Deaths and Crucial At‑Risk 
Populations
Various factors are associated with increased risk of over-
dose death in people who use opioids (PWUO). These 
include individual and behavioural risk factors, such as male 
sex, older age, intravenous (IV) use, co-administration of 
other sedative drugs (e.g. benzodiazepines, alcohol), and 
irregular patterns of use (probably due to variability of dose) 
[41]. Sadly, many overdose deaths conform to Hans Fal-
lada’s book title “Every Man Dies Alone”, as a significant 
number (approximately 30%) of opioid overdose fatalities 
happens when the drug is taken in the absence of other peo-
ple [42]. It is also a serious problem that that those around 
the individual often do not understand that the victim is not 
sleeping, but in imminent danger from an overdose [27].
Different types of opioid overdose victims die at different 
times after injection. In heroin overdose, the time course of 
opioid metabolites in post-mortem cases indicated that most 
victims stayed alive for more than 30 min, indicating a win-
dow for intervention within at least this time frame [43, 44]. 
However, in 44% of the 145 fatal cases, signs of rapid-onset 
collapse were also observed. The time frame for interven-
tion may nevertheless be shorter with fentanyl overdoses, as 
anecdotal reports of immediate deaths in 14 subjects with 
needle/tourniquet in place (along with characteristic fenta-
nyl/metabolite ratios) suggest [45]. In the case of immediate 
deaths from fentanyl or heroin, it is possible that these may 
not be secondary to respiratory depression, but rather the 
direct effect of primary cardiovascular collapse in suscepti-
ble undernourished and dehydrated individuals.
Situational factors are important, with the prison release 
population identified as a particularly high-risk group. For 
prisoners with a previous history of heroin use by injection, 
one in 200 will be dead within a fortnight of their release 
from prison, with most deaths being caused by opioid over-
dose [46–48]. These deaths likely occur during post-release 
deliberate intoxication, where, following a period of absti-
nence and consequent loss of tolerance, a previously regular 
dose may now lead to fatal overdose.
A similar clustering of deaths is seen after discharge from 
hospital or abstinence-based residential rehabilitation [49, 
50], and the explanation is likely similar. In addition, those 
in abstinence-based outpatient treatment are at increased risk 
if they then relapse [51].
The importance of this clustering characteristic is that it 
should direct both policymakers and clinicians to points of 
transition in care and setting that would benefit from pre-
ventive measures and emergency interventions, including 
THN. The target population for THN crucially also includes 
PWUO who are outside the treatment system. We need to 
remember that treatment markedly reduces the risk of over-
dose death.
A different type of clustering is seen with outbreaks of over-
dose deaths in communities, which occur with the presumed 
arrival and distribution of a particularly potent batch of heroin 
or contaminated supply (e.g. with added fentanyl). Certainly, 
this accounts for some of the clusters of deaths, but it is unclear 
why this does not then lead to modification of drug-taking 
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behaviour (e.g. avoiding this supply, or taking a smaller dose), 
and it is likely that other factors, as yet unidentified, lie behind 
some of these time-limited geographical clusters.
4  History of Naloxone for the Emergency 
Management of Opioid Overdose
4.1  Initial Development and Testing (1960s)
Naloxone (N-alyllnoroxy-morphone) hydrochloride (CAS 
Number: 357-08-4) was first synthesised from thebaine in 
New York in 1960 by Dr. Jack Fishman and Dr. Mozes J. 
Lewenstein, whose patent described naloxone as a “more 
potent antagonist to the respiratory depressive effects of 
potent analgesics than the antagonists hitherto known” [52, 
53]. Its molecular formula is  C19H21NO4HCl (molecular 
weight 363). Naloxone hydrochloride is a white-to-slightly-
off-white powder and is soluble in water, dilute acids and 
strong alkali. It is slightly soluble in alcohol and practically 
insoluble in ether and chloroform. Naloxone has a fat-water 
partition coefficient 20 times that of morphine and similar 
to meperidine. Its pKa3 is 7.94 [54]. The chemical structure 
of naloxone is shown in Fig. 3.
4.2  Entry into Clinical Practice (1970s Onwards)
The US Food and Drug Administration (FDA) approved 
naloxone in 1971 as a prescription-only medication for intra-
venous (IV), intramuscular (IM) and subcutaneous adminis-
tration for reversing the effects of opioids. Naloxone entered 
international clinical practice in the following years and was 
included as a specific antidote (i.e. in the formulation of 
0.4 mg in 1-mL ampoules) in the World Health Organiza-
tion’s Model List of Essential Medicines in 1983 [55, 56]. 
Owing to its unique effectiveness and safety profile, nalox-
one has become the treatment of choice for reversing opioid 
overdose in hospital emergency departments and ambulance 
services.
4.3  Community‑Based Naloxone (1990s)
The first serious consideration of THN occurred in a 1996 
BMJ editorial [57], which described how emergency nalox-
one kits could be pre-provided for emergency use to the fol-
lowing groups:
1. individuals at high risk of overdose, e.g. those leaving 
emergency care following overdose and those who lost 
tolerance as a result of detoxification, incarceration or 
abstinence-based treatment;
2. patients enrolled in treatment programmes; and
3. active users.
People who use opioids were described as the primary 
target group for THN because they are at risk of future 
overdose themselves and highly likely to be in a position to 
intervene in someone else’s overdose. Indeed, PWUO voiced 
strong support of THN provision. A London-based survey of 
PWUO [7] estimated that two thirds of witnessed overdose 
deaths could have been avoided with THN, and nearly 90% 
of respondents who had witnessed an overdose stated that 
they would have used the medication had it been available. 
Subsequent studies identified the willingness of PWUO [58, 
59] and family members [8] to be trained in overdose man-
agement and naloxone administration.
Early implementation of THN was made possible through 
user advocates working with physicians willing to prescribe 
naloxone despite medicolegal uncertainty or explicit bar-
riers. Take-home naloxone provision first occurred in the 
late 1990s and early 2000s, in the USA (Chicago, San 
Francisco), Germany (Berlin), the UK (Jersey) and Italy 
(Turin, Bologna, Padua) [60–69]. The identification of legal 
pathways for THN provision from the mid-2000s onwards 
facilitated the introduction of first national and state-wide 
programmes in parts of Europe and USA.
5  Pharmacokinetics and the Development 
of New Non‑injectable Naloxone
5.1  Notion of Non‑injectable Formulations: 
Potential for more Acceptable Implementation
Because injectable naloxone was not developed for layper-
son use, non-injectable naloxone formulations have been 
considered to have several implementation advantages 
for THN programmes. First, injectable medications are 
Fig. 3  Chemical structure of naloxone (anatomical therapeutic chemi-
cal code V03AB15)
3 pKa is defined as the negative base-10 logarithm of the acid dis-
sociation constant (Ka) of a solution. The lower the pKa value, the 
stronger the acid.
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intimidating for laypersons to use [70] and present logisti-
cal barriers: they require product assembly (e.g. needle and 
syringe) and training in administration. Surprisingly, even 
among experienced PWUO, nearly three out of four (74%) 
preferred naloxone nasal spray to injectable devices [71]. 
Second, with use of naloxone by injection, there is the risk 
of needle-stick injury. Third, non-injectable naloxone could 
likely overcome regulatory obstacles (e.g. prescription-only 
status for injectable medications) and be provided to a wider 
workforce (e.g. hostel staff, outreach workers, police).
5.2  Routes of Administration
Naloxone was originally developed and FDA approved as an 
injectable formulation for use by medical professionals (see 
above). The IV route requires skilled personnel and takes 
time to establish. Intramuscular is now the widely preferred 
parenteral route because IV carries a greater risk of expo-
sure to contaminated blood as well as risks of withdrawals 
and potential aggression. Intranasal is the simplest and fast-
est procedure, and it circumvents the contamination haz-
ard. While IV provides by far the most rapid and reliable 
response when measured from the time of administration, 
IM comes as a good second, followed closely by IN (see 
Table 1). However, when time from contact with the patient 
is the starting point in the emergency situation, IN [72] and 
subcutaneous [73] have been found to be as fast as IV. A 
potential shortcoming with the IN route is that effective 
uptake may be reduced by septal abnormalities, bleeding, 
nasal mucous, trauma and use of nasal vasoconstrictors [74].
5.3  Improvised Nasal Naloxone Kits
In the absence of licensed non-injectable naloxone for-
mulations, ‘improvised’ nasal kits (i.e. a 2-mg/2-mL pre-
filled syringe with a nasal mucosal atomizer device [MAD] 
attached) were being distributed by some North American 
THN programmes from 2006 onwards (and later also in parts 
of Scandinavia and Scotland), despite not having been for-
mally tested for safety or efficacy. This followed their use by 
EMS as well as fire fighters and police officers. (The safety 
of use of the improvised kits in medical practice is discussed 
in more detail in Sect. 6.6.)
These ‘improvised’ kits were used in many successful 
overdose reversals, and reports of problems using the kits 
were uncommon [75, 76]. For instance, in Norway, just over 
2000 ‘improvised’ THN kits were distributed in 2014–2015, 
with 277 reports of successful reversals [77, 78].
However, concern was expressed about the reliance on 
such improvised nasal sprays because the naloxone concen-
tration in the spray was dilute (1 mg/mL) [79]. Specifically, 
given the existence of licensed injectable products, the ques-
tion was raised [79] whether it was acceptable for clinicians 
to supply unlicensed improvised nasal naloxone kits for take-
home use, where no back-up of injectable naloxone would be 
available in the case of non-response (unlike the ambulance 
or hospital setting). This stirred a challenging debate among 
international experts in the field [80, 81].
Subsequent examination of patent records located data 
confirming only poor bioavailability (approximately 10% of 
dose administered) [82] and recent direct pharmacokinetic 
comparison of the improvised kits vs. the new concentrated 
naloxone nasal spray formulations found bioavailability of 
only approximately 20% with the improvised kits vs. more 
than 40% with the new concentrated naloxone sprays [83]. 
Nevertheless, the evident successful reversals of opioid over-
doses with these improvised kits [75–77] should raise ques-
tions about the dose necessary for layperson reversal which, 
in these instances, appears to have been achieved with much 
lower absorbed concentrations of naloxone.
5.4  Regulatory Criteria for the Development 
of Non‑injectable Naloxone Products
In response to rising overdose mortality rates, the US FDA, 
Centers for Disease Control and Prevention, National Insti-
tute on Drug Abuse, and Office of the Assistant Secretary for 
Health and Human Services sponsored a stakeholder meet-
ing in 2012 to encourage the development of non-injectable 
naloxone products suitable for layperson use in community-
based settings. Following the meeting, the National Institute 
on Drug Abuse announced that it would provide funding for 
the development of user-friendly naloxone devices (i.e. IN 
rather than injection) [84].
The key regulatory criteria for any New Drug Application 
[85, 86] involved that naloxone would need to be absorbed into 
Table 1  Characteristics of naloxone administration routes
IM intramuscular, IN intranasal, IV intravenous
a Comparable doses
Route Skills Time to establish Time to onset Reliability Risk for  withdrawala
IV High Medium + Rapid High High
IM Some Medium Medium + Medium to high Moderate
IN Little Short Medium Unknown Moderate
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the bloodstream rapidly, given the emergency situation, and in 
a quantity sufficient to effect quick reversal of opioid-induced 
respiratory depression. The reference for any candidate non-
injectable product would be injectable naloxone, administered 
by the licensed IM, IV and subcutaneous routes [9].
5.4.1  Identification of Candidate Routes of Administration 
for Non‑injectable Products
Naloxone has a very low oral and rectal bioavailability of 
1–2% and 15%, which makes these routes unsuitable for 
emergency naloxone [87]. Strang et al. [88] thus explored 
candidate routes of administration for THN use. Only the 
transmucosal routes IN, buccal and sublingual met the 
required characteristics. Transmucosal uptake bypasses 
first-pass hepatic elimination. Among these three routes, 
approved products only exist for IN administration (see 
below). In the following section, we describe the pharma-
cokinetics of injectable naloxone as the reference for the 
development of non-injectable products.
5.5  Naloxone Pharmacokinetics
Naloxone is rapidly and extensively metabolised mainly by 
glucuronidation to the inactive compound naloxon-3-glu-
curonide (N3G) thought to be primarily by the liver at that 
time [89]. Ngai et al. [90] and Berkowitz [91] reported initial 
distribution and terminal half-lives of 4 and 64 min. Recent 
pharmacokinetic studies [92–95] confirmed terminal elimi-
nation half-lives of 60–120 min after IV administration of 
0.4–1.0 mg (see Table 2). It should be noted that arterial 
and venous serum concentrations are similar [95]. Older 
studies have shown a volume of distribution of 200 L and a 
total clearance of about 2 L/min [89, 96]. However, Yassen 
et al. [97] and Skulberg et al. [94, 98] reported volumes of 
distribution of about 320 L and clearances between 3 and 4 
L/min. This is two to three times higher than the maximal 
liver clearance; consequently, naloxone must be exposed to 
significant extrahepatic metabolism.
For IM naloxone (see Table 4), the mean time to maxi-
mum concentration and mean dose-corrected maximum 
serum concentration (Cmax) varied from 8 to 24 min and 
1.55–4.66 ng/mL, respectively. The latter is far lower than 
those of IV 14.1–18.6 ng/mL (Table 2). However, dose-cor-
rected area under the curves (AUCs) were as expected rather 
similar for injectable naloxone (see Tables 2, 4), although 
AUCs were both AUC inf and AUC 0–t for IM.
5.5.1  Intranasal Route of Administration
The nose is readily available and presents the advantage that 
laypeople are already familiar with the use of nasal sprays. 
People who use opioids generally preferred nasal spray over 
injectable naloxone [71]. The mucosa of the nose is exten-
sively perfused. Its endothelial lining is very open to the 
external environment. Moreover, its mucosa is constantly 
cleared by mucociliary transport, requiring that uptake 
takes place within about 15 min. However, the nose cannot 
accommodate spray volumes greater than 0.15 mL, as excess 
volume will be lost as nasal drip or post-nasally [99]. For 
this reason, many THN programmes have moved from using 
‘improvised’ nasal kits (i.e. 2-mL syringes with attached 
MAD) to distributing approved nasal spray products, which 
deliver a volume of 0.1 mL.
Table 2  Pharmacokinetics of intravenous naloxone
AUC area under the curve, AUC last, Cmax maximum serum concentration, min minutes, T1/2 half-life, Tmax time to maximum concentration
a Arithmetic mean (standard deviation)
b Arithmetic mean (95% confidence interval)
c Median (minimum, maximum)
d Geometric mean (90% confidence interval)
e Geometric mean (% coefficient of variation)
f Partly under opioid exposure
References Dose (mg) N Cmax (ng/mL) Dose-
corrected 
Cmax
Tmax (min) AUC last (ng × h/mL) Dose-
corrected 
AUC 
T1/2 (min)
Skulberg et al. [94] 0.4 22 7.44 (9.67)a 18.6 3.5 (4.2)a 1.84 (1.49)a 4.6 74.3 (32.1)a
Tylleskar et al. [95]f 1.0 12 14.1 (9.98–18.2)b 14.1 Not reported 3.65 (3.05–4.27)b 3.65 Not reported
McDonald et al. [92] 0.4 34 5.94 (92.9)e 14.9 2 (1–5)c 2.05 (0.4)e 5.13 75 (13)a
Tylleskar et al. [93] 1.0 12 14.2 (9.13–19.2)b 14.2 2.25 (1.70–2.80)b 4 (3.45–4.55)b 4 70.1 (60.1–78.7)b
Gufford et al. [103] 2.0 6 – – – 10.8 (8.92–13.2)d 5.4 91 (64–130)d
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5.5.2  Approved Nasal Spray Products
Four high-concentrate and approved products,  Narcan® 
[100],  Nyxoid® [92],  Nalscue® (in France), and  Ventizolve® 
(12 European countries) [94] utilise the Aptar Pharma (here-
after referred to as ‘Aptar’) unit dose spray (0.1 mL, see 
Table 3).  Narcan® by Adapt Pharma (hereafter referred to as 
“Adapt”) was the first approved nasal spray product, having 
received FDA approval in November 2015 [101] and Health 
Canada approval in October 2016. Adapt subsequently also 
received regulatory approval for a 2-mg/0.1-mL version of 
Table 3  Comparison of nasal sprays approved in different countries
EMA European Medicines Agency, FDA US Food and Drug Administration, n/a, NR, OTC, temp.
a A 2-mg/0.1-mL version of  Narcan® by Adapt was approved in North America but, to our knowledge, has never been introduced in clinical prac-
tice. Kreiter et al also report, in their 2019 paper, that they had been informed by Adapt Pharma, the manufacturer, that the 2mg product had not 
been marketed and that there were no current plans to launch it
b All formulations in this table are reported as naloxone hydrochloride, with the 1.8 mg of naloxone listed in Nyxoid being equivalent to 2 mg of 
naloxone hydrochloride
c A generic version of the 4-mg/0.1-mL Narcan nasal spray by Teva Pharmaceuticals received FDA approval in April 2019 (https ://www.fda.gov/
drugs /devel opmen tappr ovalp roces s/howdr ugsar edeve loped andap prove d/druga ndbio logic appro valre ports /andag eneri cdrug appro vals/)
Product name Narcan® Nalscue® Nyxoid® Ventizolve®
Manufacturer Adaptc Indivior Mundipharma Den norske Eterfabrikk (DnE)
Regulatory status: licensed in USA (November 2015)
Canada (October 2016; OTC)
France: July 2016 (temp.), 
July 2017 (marketing 
authorisation)
Europe (EMA, 
September 
2017)
12 European countries (May 
2018)
Formulationb 4 mg/0.1 mL, (2 mg/0.1 mL)a 0.9 mg/0.1 mL 2 mg/0.1  mLb 1.4 mg/0.1 mL
Relative bioavailability 46% 37% 47% n/a
Absolute bioavailability NR 47% 52–54%
Table 4  Pharmacokinetics of intramuscular naloxone
AUC area under the curve, AUC inf, min minutes, AUC last, Cmax maximum serum concentration, opioid partly under opioid exposure, T1/2 half-
life, Tmax time to maximum concentration
a Arithmetic mean (standard deviation)
b Arithmetic mean (95% confidence interval)
c Geometric mean (% coefficient of variation)
d Median (minimum, maximum)
e Geometric mean (90% confidence interval)
f AUC last
References Dose (mg) N Cmax (ng/mL)c Dose-
corrected 
Cmax
Tmax (min)d AUC inf (ng × h/mL)c Dose-
corrected 
AUC 
T1/2 (min)c
Skulberg et al. [94] 0.8 22 3.73 (3.34)a 4.66 13.6 (15.4)a 3.43 (0.66)a 4.29 84.8 (26.5)a
Skulberg et al. 
[98]opioid
0.8 12 3.62 (2.64–4.60)b 4.53 7.75 (5.01–10.5)b 4.07 (3.28–4.87)b,f 5.08 69.7 (59.5–79.8)b
McDonald et al. [92] 0.4 34 1.27 (55.8) 3.18 10 (4–90) 2.01 (17.7) 5.03 81 (16)a
Gufford et al. [103] 2.0 6 3.1 (2.3–4.2)e 1.55 22.5 (10–60)d 7.23 (6.43–8.12)e 3.61 100 (89–111)e
Evzio (Kaleo, 2016) 0.4 30 1.2 (51.4) 3 15.0 (4.80–73.8) 1.9 (23.4) 4.75 78 (38)
0.4 24 1.3 (62.9) 3.25 15.0 (5.40–50.4) 2.0 (16.3) 5.0 96 (28.9)
0.4 × 2 24 2.2 (47.4) 2.75 12.6 (5.40–51.0) 3.8 (19.1) 4.75 90 (23.7)
2 24 7.9 (45.8) 3.95 15.0 (7.8–40.2) 10.3 (15.2) 5.15 90 (23.7)
Krieter et al. [100] 0.4 29 0.90 (31.2) 2.25 24.0 (6.0–126) 1.8 (22.7) 4.5 78 (27.8)c
Gufford et al. [103] 2.0 6 3.1 (2.3–4.2)e 1.55 22.5 (10–60)d 7.23 (6.43–8.12)e 3.61 100 (89–111)e
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the spray, but this product is not commercially available at 
the time of writing.4
A competitor product by Indivior  (Nalscue®; 0.9-mg/0.1-
mL formulation, also in the Aptar device) failed to receive 
FDA approval because the nasal spray was found not to be 
absorbed sufficiently rapidly relative to IM naloxone [102]. 
Nonetheless, this product secured a marketing authorisation 
in France in July 2017.
In Europe, Mundipharma received European Medicines 
Agency approval in November 2017 for a 2-mg/0.1-mL 
naloxone hydrochloride dihydrate (i.e. 1.8-mg naloxone 
base;  Nyxoid®) concentrated nasal spray for delivery by the 
same Aptar device as the other new nasal sprays, and has 
subsequently been rolled out progressively across much of 
Europe. The pharmacokinetics of the spray formulation have 
been published [92].
In June 2018, the Norwegian company AS Den Norske 
Eterfabrikk received regulatory approval in 12 European 
countries for a 1.26-mg base (1.4 mg hydrochloride) nalox-
one nasal spray  (Ventizolve®); its pharmacokinetics has been 
published [94].
5.5.3  Intranasal Naloxone: Pharmacokinetics
As part of the development of these high-concentrate 
naloxone spray products (and their application for regula-
tory approval), a number of recent studies have explored 
the pharmacokinetics of IN naloxone (see Table 4). Nasal 
naloxone doses in these studies ranged from 0.8 to 8 mg. 
(In the small study [n = 6] by Gufford et al. [103], 0.1- and 
0.2-mL volumes were used. Edwards et al. [74] also studied 
the MAD delivering 2.0 mL).
The high-concentrate IN formulations all have reason-
ably rapid uptake with a mean time to maximum concen-
tration of 15–30 min, which is somewhat slower than the 
8–24 min for the IM formulations (Tables 3, 4; see also 
Fig. 4). The mean dose-corrected Cmax for IN varied from 
1.29 to 2.04 ng/mL, which is lower than for IM (mean 
1.55–4.66 ng/mL). A dose–serum concentration relation-
ship was repeatedly reported. Dose-corrected AUCs were 
far lower (1.40–3.34 ng/mL) than for injectable formula-
tions. This conforms with the relative bioavailability of IN to 
IM of about 44–54% for the high-concentrate formulations, 
while only 10–15% was found for the dilute formulations 
[74]. However, Skulberg et al. [98] found a far higher bio-
availability (75%) in subjects under exposure to the opioid 
remifentanil for 2 hours of the 6-hour study. Whether this 
is a specific remifentanil or generic opioid effect remains 
unknown, but a potential higher bioavailability under an 
opioid may have implications for future regulatory studies 
of nasal administration.
Absolute bioavailability for concentrate nasal sprays var-
ied from 47 to 54% [92, 93]. Most importantly, these high-
concentrate sprays deliver therapeutic doses (0.4–2.0 mg) 
in a single 0.1-mL spray, and a second spray gives a pro-
portionate rise in serum concentrations. In contrast, dilute 
nasal spray (2 mg/2 mL) administered via the MAD only 
had 11–20% absolute bioavailability, implying that a sub-
therapeutic dose of approximately 0.2–0.4 mg was delivered 
[74, 82, 83]. A recent study confirmed that, even after two 
administrations, dilute nasal spray (2 mg/2 mL, administered 
via a MAD) failed to achieve naloxone plasma concentra-
tions comparable to concentrate nasal sprays (2 mg/0.1 mL, 
4 mg/0.1 mL) at any time [83].
Fig. 4  Schematic of the 
pharmacokinetics of intranasal 
(IN) 2 mg, intramuscular (IM) 
0.4 mg and intravenous (IV) 
0.4 mg naloxone. PK pharma-
cokinetic
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When comparing IV with IM and IN, it is evident that 
a comparable dose given IV generates immediate and far 
higher initial serum concentrations. It is also important to 
acknowledge that the Cmax for the 2- to 4-mg doses of IM 
(e.g.  Evzio®) and IN are far higher than those of the 0.4-mg 
IM comparator. This is relevant for the discussion below on 
the risk of withdrawal symptoms.
Skulberg et al. [94] used pharmacokinetic modelling 
to illustrate the relationship between first-responder nasal 
naloxone dosing and subsequent IM administrations by 
ambulance paramedics 10 min later. First-responder dos-
ing of 1.4 mg IN produced plasma concentrations that were 
higher than 0.4 mg IM 10 min later all the time up to 20 min 
but lower than for 0.8 mg IM in the first 15 min. However, 
the combined 1.4 mg IN and 0.4 mg IM 10 min later were 
higher than 0.8 mg IM alone at the same time. It was con-
cluded that it was beneficial to administer IN for up to 2 min 
before an ambulance paramedic delivered a 0.4-mg IM dose.
6  Pharmacodynamics, and Efficacy 
and Safety of Naloxone for the Emergency 
Management of Opioid Overdose
6.1  Pharmacodynamics
Naloxone is essentially a pure competitive MOR antagonist. 
Its affinity compares well with the opioid agonists such as 
morphine, methadone and fentanyl, thus being capable of 
reversing their actions (see Table 5) [104]. It is estimated 
that a dose of 0.9 mg/70 kg occupies about 50% of brain 
receptors in opioid-naïve subjects [105].
Animal testing characterised naloxone as a “potent, rapid-
acting, and relatively pure narcotic antagonist”, which coun-
teracted the effects of a range of opioid agonists, including 
morphine and methadone, without agonist activity of its 
own [106, 107]. In humans, it was found that 0.35 mg/70 kg 
of naloxone had a greater effect on opioid-induced respira-
tory depression than 150 and 20 mg/kg of nalorphine and 
levallorphan, respectively [108]. Naloxone did not, in con-
trast to the two others, induce respiratory depression in sub-
jects not given an opioid. Therefore, it was recommended 
that naloxone should be the opioid antagonist of choice for 
clinical use [108].
The partial agonist buprenorphine is different (see 
Table 6). It has a high affinity to MOR and dissociates 
slowly, in contrast to the much faster dissociation of nalox-
one [109]. Thus, naloxone reversal of the action of buprenor-
phine is slow and far larger doses are required [110].
Naloxone equilibrates rapidly with the site of action in the 
brain as shown by its blood-effect site equilibration half-life 
of 6.5 min [97], a little slower than that of fentanyl [111]. It 
is speculated whether an active transport system is involved 
in this uptake process [112]. In a very recent, positron emis-
sion tomography study of nasal naloxone in healthy vol-
unteers, carfentanil was used for initial characterisation of 
MOR availability. The MOR occupancy was slightly delayed 
to serum concentrations, and half of peak occupancy was 
reached at 10 min. The 4-mg IN dose gave up to 85% MOR 
occupancy [113]. These experimental findings concord with 
the clinically observed rapid onset of action of naloxone.
Berkowitz [91] showed in the rat that brain concentrations 
of subcutaneous naloxone rose as rapidly as serum concen-
trations and stayed steadily above these during a parallel 
decline. For the agonist morphine, both uptake and egress 
from the brain lagged its serum concentrations all the time.
Kaufman et al. [114] reported that naloxone in healthy 
men had a dose-dependent duration of about 1.5 hours on 
morphine-induced respiratory depression. Onset of action 
after about 0.35 mg/70 kg IV was 2–3 min, peaking at 
25 min. A dose of about 0.33 mg/70 kg was required to 
reduce the effect of 12 mg of morphine to that of 4 mg.
Pupilometers were used by Gufford et al. [103] to study 
the attenuating effect of naloxone (2 mg IM and IN) on 
4 mg of oral alfentanil (with or without grapefruit juice). 
However, only moderate increases (about 20%) of the pupil 
diameter were found. Skulberg et al. [98] used target-con-
trolled infusion of remifentanil to create steady-state opioid 
agonism. Intramuscular naloxone (0.8 mg) reversed pupil 
size significantly and was superior to the same IN dose. In 
a subsequent paper from the same group [95], the duration 
of action of 1 mg of naloxone IV was 120 min. Moreover, a 
minimum effective concentration of naloxone in steady state 
of 0.5 ng/mL was established.
Middleton et al. [115] compared subjective effects and 
pupil diameter in ten non-dependent PWUO after giving 
2 mg and 8 mg of buprenorphine, alone or in combination 
with 0.5 mg and 2 mg of naloxone. No statistically signifi-
cant differences were found between formulations. Experi-
mental studies of the effects of naloxone in opioid addicts 
are rare. Loimer et al. [116] provoked abstinence with nalox-
one for diagnostic and therapeutic purposes in dependent 
Table 5  Opioid receptor affinities (modified from [104])
P partial agonist action, + agonist, − antagonist
Drug Opioid receptors
Mu (μ) Gamma (γ) Kappa (ϰ)
Naloxone − − − − − −
Morphine +++ No effect No effect
Methadone +++ No effect No effect
Fentanyl +++ No effect +
Buprenorphine P No effect − −
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PWUO in Pakistan, assessing withdrawal using an Objective 
Opioid Withdrawal Scale. Peak onset of action was within a 
few minutes for IV, and about 15 min for IM and IN. Dura-
tions of actions exceeded 90 min for all administrations.
Overall, several factors affect the outcome of nalox-
one antagonism (see Table 7). Most of these factors are 
unknown in an overdose situation, where it is not clear what 
drugs were consumed. Therefore, naloxone should always 
be titrated to restore adequate respiration and cognitive 
function.
6.2  Clinical Effects
Naloxone can reverse serious effects of opioids such as res-
piratory depression and stupor. Naloxone does not cause 
physical or psychological dependence and has virtually no 
effect in a healthy non-dependent person. Naloxone doses 
Table 6  Pharmacokinetics of intranasal naloxone
AUC area under the curve, AUC inf, AUC last, Cmax maximum serum concentration, FIM,min minutes, opioid partly under opioid exposure, T1/2 half-
life, Tmax time to maximum concentration
a Arithmetic mean (95% confidence interval)
b Geometric mean (% coefficient of variation)
c Median (minimum, maximum)
d Arithmetic mean (standard deviation)
e Geometric mean (90% confidence interval)
f AUC last
g Absolute bioavailability
References Dose (mg) N Cmax (ng/mL)b Dose-
corrected 
Cmax
Tmax (min)c AUC inf (ng × h/
mL)b
Dose-
corrected 
AUC 
T1/2 (min)b FIM%
Skulberg et al. 
[94]
1.4 22 2.36 (0.68)d 1.69 20.2 (9.4)d 2.84 (0.94)d 2.03 73.0 (20.2)d 52
2.8 (1.4 × 2) 22 4.18 (1.53)d 1.49 20.7 (9.54)d 5.47 (1.89)d 1.95 69.8 (12.8)d
Skulberg et al 
[98]opioid
0.8 12 1.63 (1.25–
2.02)c
2.04 28.0 (22.0–
34.0)c
2.67 (2.08–
3.25)c
3.34 63.7 (59.2–
68.2)c
75opioid
Krieter et al. 
[100]
2 29 3.1 (51.4) 1.55 18 (18–126) 4.7 (29.8) 2.35 114 (34.6) 51.9
4 29 5.3 (44.6) 1.33 30 (12–60) 8.5 (39) 2.13 132 (34.6) 46.2
4 (2 × 2) 29 6.5 (32.3) 0.81 18 (12–36) 9.7 (26.7) 2.43 144 (31.7) 53.5
8 (4 × 2) 29 10.3 (38.1) 1.03 18 (12–609 15.8 (23.1) 1.98 132 (39.0) 43.9
Tylleskar et al. 
[93]
0.8 12 1.45 (1.07–
1.84)c
1.81 17.9 (11.4–
24.5)c
1.65 (1.28–
1.72)c,f
2.06 89.7 (76.8–103)c 54 g
1.6 (0.8 × 2) 12 2.57 (1.49–
3.66)c
1.61 18.6 (14.4–
22.9)c
3.08 (2.05–
4.13)c,f
1.93 79.0 (65.3–
92.7)c
52 g
McDonald et al. 
[92]
1 32 1.51 (50.2) 1.51 15 (10–60) 2.69 (40.5) 2.69 80 (23)d 50.2
2 33 2.87 (49.6) 1.44 30 (8–60) 4.97 (38.5) 2.49 84 (30)d 46.8
4 (2 × 2) 33 6.02 (54.5) 1.51 15 (10–60) 10.07 (35.8) 2.52 102 (28)d 48.1
Gufford et al. 
[103]
1.0 6 5.7 (3.3–10)e – 12.5 (5–15)c 4.7 (3.33–6.65)e 2.35 61 (53–72)e 75
2.0 (1 × 2) 6 3.0 (1.7–5.3)e 1.5 5.0 (5–15)c 2.8 (1.95–4.0)e 1.40 80 (56–113)e 44
Evzio (Kaleo, 
2016)
2/2 mL 36 1.3 (48.3) 0.65 15 (4.2–40.8) 1.5 (31.6) 0.71 90 (18.5) 14.6
2/2 mL 36 0.7 (52) 0.35 19.8 (4.8–60) 1.1 (35.1) 0.54 90 (22.9) 11.1
Table 7  Factors affecting opioid reversal by naloxone
Drug Blood brain equilibration Egress from brain Dissociation rate Terminal half-life
Naloxone Rapid Rapid Rapid Short
Morphine Slow Slow Medium
Methadone Rapid? ? ? Long
Fentanyl Rapid Medium ? Medium
Buprenorphine ? ? Slow Long
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up to 1 mg/kg have been tolerated, while 4 mg/kg was found 
to provoke undesired behavioural effects [117]. As noted 
above, naloxone also reverses skeletal muscle rigidity from 
fentanyl and its analogues [30, 31].
The most rewarding use of naloxone is in opioid over-
dose. Opioid overdose is characterised by stupor, impaired 
respiration and pin-point (miotic) pupils. Respiratory fail-
ure may lead to hypercapnia (also called hypercarbia) and 
hypoxemia, which may eventually be fatal. The best predic-
tor of a successful response to naloxone in overdose is the 
miotic pupil [118].
6.3  Recurrence of Toxicity
Naloxone is a short-acting drug compared to the duration of 
action of many of the opioids [119]. In overdose, the dura-
tion of action of methadone, extended-release morphine, 
buprenorphine, extended-release oxycodone and fentanyl 
may exceed 12 hours. Thus, the effect of naloxone may 
wane before the respiratory depression by these opioids has 
ended [120]. In such cases, hospitalisation and repeat doses 
or continuous infusion of naloxone may be required [121]. 
Fortunately, the mortality rate from re-intoxication is low 
(< 1%) [122, 123].
6.4  Acute Opioid Withdrawal Symptoms
In opioid-dependent subjects, administration of naloxone 
may produce acute onset of withdrawal symptoms such as 
agitation, nausea, vomiting, piloerection, diarrhea, lacrima-
tion, yawning and rhinorrhea [116]. Tachycardia and hyper-
tension are potentially serious circulatory effects, while vio-
lent behaviour and drug craving are far from trivial. Opioid 
withdrawal is not considered life threatening [124].
Buajordet et al. [125] conducted a prospective observa-
tional study in 1192 episodes of opioid overdose. Suspected 
adverse events from naloxone were reported in 45% of cases. 
Thirty-three percent had opioid withdrawal (gastrointestinal 
disorders, aggressiveness, tachycardia shivering, sweating 
and tremor), and 15% had headaches and seizures. Only 
0.3% were hospitalised for an adverse event. The initial 
naloxone doses administered were 0.4–0.8 mg IM combined 
with an IV dose of 0.4 mg.
6.5  Dosing Guidelines for Opioid Overdoses
Recently, a comprehensive review paper (recommended for 
the interested reader) on naloxone dosing for opioid reversal 
was published [28]. The initial doses of naloxone commonly 
recommended for overdose are 0.4–2.0 mg IV or IM [124], 
with doses surpassing 0.8 mg potentially increasing the risk 
of significant withdrawal symptoms [9]. The duration of 
action of naloxone is 20–90 min depending on dose and the 
situation of the patient [119]. As reported above, a duration 
of action of about 90–120 min of 1 mg of naloxone was 
found in healthy volunteers and opioid-dependent individu-
als [95, 116]. Doses should be titrated every 2–3 min accord-
ing to response for a total dose of up to 10 mg.
6.5.1  Special Populations
Care should be taken in the elderly, patients with preexist-
ing cardiovascular disease and in those receiving potentially 
cardiotoxic drugs. The limited available data on naloxone 
use in pregnant women are not sufficient to inform a drug-
associated risk. However, there are risks to the foetus of the 
opioid-dependent mother with the use of naloxone (Evzio 
summary of product characteristics). Children (aged 5 years 
and below) require relatively higher doses such as 0.1 mg/
kg because of more severe intoxications [119]. However, 
lower initial doses (0.01 mg/kg) are also recommended, pos-
sible because opioid withdrawal may be life threatening in 
neonates.
6.5.2  Dosing of ‘Take Home Naloxone’
The situation is different when it comes to THN. The 
advantage of THN is that naloxone can be administered at 
an earlier stage, prior to ambulance arrival, similar to lay-
person use of defibrillators in cardiac arrest. At present, the 
naloxone dose required in this situation is controversial (see 
below).
6.5.3  Naloxone Dosing for Fentanyl Overdoses
Severe intoxications of long duration resulting from swal-
lowing fentanyl-adulterated hydrocodone/paracetamol 
(acetaminophen) tablets were reported [121]. One of the 18 
overdose victims died. Seventeen required naloxone boluses, 
and four needed a prolonged infusion (26–39 hours) of 
naloxone.
Examination of about 95,000 cases in the national EMS 
data has also documented an overall increase in the severity 
of US opioid overdoses [126]. The use of multiple naloxone 
doses increased from about 15% in 2012 to 18% in 2015 
[126]. In contrast, Bell et al. [127] found that systemic dos-
ing of 0.4 mg naloxone (IM) did not increase from 2013 to 
2016, despite an increase in fentanyl-related deaths from 4 
to 69% in the same period. More than 90% of the reversals 
were successful after two naloxone doses (0.8 mg).
As for the intoxications resulting in immediate deaths, 
only anecdotal reports are available on the effect of nasal 
naloxone on fentanyl overdoses. Somerville et  al. [27] 
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summarised characteristics of assumed fentanyl overdoses 
in Massachusetts during 2014–2016. In 5% of deaths, lay-
persons administered naloxone. Among those who received 
nasal naloxone (2 mg/2 mL), respondents reported that 83% 
required two (equivalent to about a 0.4- to 0.8-mg systemic 
dose) or more doses before a response was seen. In addition 
to the limited use of naloxone by laypersons, rapid bystander 
response was inhibited by a lack of bystanders (18%), spatial 
separation of decedents from bystanders (e.g. person was 
in another room of the house [58%]), lack of awareness of 
the decedent’s drug use (24%), intoxication of bystanders 
themselves (12%), failure to recognise overdose symptoms 
(11%) or bystander assumption that the decedent had gone 
to sleep (15%). Clear evidence that a bystander was unim-
paired, witnessed the drug consumption and was present 
during an overdose (i.e. able to respond immediately) was 
reported in 1% of the fentanyl overdose decedent charts. 
Moderate titrated doses of nasal naloxone appeared effec-
tive when given.
6.6  Safety and Efficacy of Non‑approved Nasal 
Formulations
6.6.1  Randomised Controlled Studies
A few open-label randomised clinical studies in the pre-hos-
pital setting have evaluated IN vs. IM naloxone. Both Kerr 
et al. [128] and Kelly et al. [129] compared an upper-level 
initial dose of 2 mg IM with a 2-mg IN dose. Primary out-
comes in these studies were similar, with adequate respira-
tion and Glasgow Coma Scale response at 8–10 min. In the 
study by Kelly et al. [129], IM did somewhat better than IN 
(2-mg/5-mL formulation; 82% vs. 63% successful reversals), 
compared to 78% and 72% reported in the Kerr et al. [128] 
paper (2-mg/2-mL IN formulation). The safety of IN nalox-
one was not inferior to IM. This is somewhat surprising, 
given that for dilute IN formulations (≤ 1 mg/mL) the time to 
maximum concentration is slower and dose-corrected Cmax/
AUCs are generally lower.
6.6.2  Observational Studies
A retrospective study from Boston, USA, examined the use 
of nasal naloxone (2 mg/2 mL by MAD syringe) by basic life 
support providers [130]. After dosing, patients were trans-
ported to an emergency department. Nasal naloxone reversed 
overdose in 95% of 793 patients, and only 9% required addi-
tional naloxone. Ninety-seven percent of patients had taken 
heroin, 3% had taken other opioids.
In another retrospective study, 2 mg/2 mL of nasal nalox-
one (MAD syringe) was administered by law enforcement 
officers and basic life supporters. The overdose victims 
(n = 2166) were subsequently managed by paramedics [131], 
and 9% needed at least one additional naloxone dose.
Despite somewhat different follow-up procedures in these 
studies, low rates for re-dosing (9%) were reported. This 
indicates that nasal systemic doses equivalent to 0.2–0.4 mg 
IV/IM [74, 82], which may be below the lowest World 
Health Organization-recommended starting dose of 0.4 mg 
[9], seem both safe and effective in most circumstances 
when given in medical settings (in contrast to layperson 
administration).
6.7  Safety of Approved Nasal Formulations
As the basis for approval of naloxone nasal sprays, the 
FDA requires that any new formulation must prove that it 
obtains a serum concentration similar to, or higher than the 
0.4-mg IM reference in healthy volunteers [132]. It should 
be noted that there is a discussion within the FDA whether 
the comparator dose should be increased [133]. The focus 
of the FDA is on the first 10–15 min after administra-
tion. To achieve this goal, owing to the somewhat slower 
IN uptake, a nasal formulation must systemically deliver 
relatively more naloxone than IM leading to a considerable 
“overshoot” of the Cmax and the AUC (i.e. amount entering 
the systemic circulation). This carries a significant risk for 
naloxone overdosing that may provoke withdrawal symp-
toms. Although opioid withdrawal is not considered fatal, 
it is not trivial. Experiencing withdrawal is feared among 
people who use opioids. Qualitative interviews in Scottish 
and US cohorts of PWUO identified negative views on 
naloxone administration in the emergency room and the 
harm caused, such as acute withdrawal, aggression, self-
discharge and further drug seeking activity [134, 135]. 
These attitudes were missed by ordinary observational 
studies. Indeed, these behaviours and further drug seeking 
activity perhaps constitute behaviourally mediated toxic-
ity [136].
The relatively high success rates reported by first respond-
ers using one or two sub-therapeutic doses of naloxone (sys-
temic equivalents of about 0.2–0.8 mg) raises the possibil-
ity that many overdoses may be over-treated with the new 
approved devices delivering naloxone in the upper recom-
mended range (e.g. to about 2 mg by injection). In a report 
concerning  Narcan® (4 mg), 74 of the 196 reported cases 
of community use had events that may, but not necessarily, 
conform to opioid withdrawal; none were life threatening 
[137]. If an intervention turns out to be labelled “withdrawal 
hazard” by the user community, this may well affect their 
decision to use the product.
Moreover, in their review of new naloxone products, reg-
ulatory bodies did not consider that characteristics of the 
nose may differ in the target population compared to healthy 
volunteers or the unexpected observation by Skulberg et al. 
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[98] of a higher nasal bioavailability under opioid infu-
sion. However, we know that all the approved nasal sprays 
deliver far higher systemic doses than doses supplied by the 
unapproved dilute nasal sprays. This should secure a very 
broad safety margin. The nasal (systemic) doses given in 
the ambulance-based randomised controlled trial in Aus-
tralia were far lower than the IM comparator [128], yet the 
two groups performed similarly, except that about one in 
five overdose cases needed “rescue naloxone” (i.e. a sec-
ond naloxone dose, this time by injection) following non-
response to improvised naloxone nasal spray (2 mg/mL). As 
a moderate “overtreatment” with naloxone is hard to docu-
ment, it can be argued that the comparator dose was higher 
than required for overdose reversal. This complies well with 
the observational studies that demonstrated unexpected 
high success rates, also in fentanyl overdoses. Therefore, 
the new purpose-developed concentrated naloxone nasal 
sprays which are being approved (dose range 1.4–4.0 mg), 
all with an option for titration with an accompanying second 
dose, are likely to offer a higher margin of safety with opioid 
overdoses, even in the era of illicit fentanyl. Nevertheless, 
the suitability of the different products will likely depend 
on the patterns of opioid use in a community, with higher 
strength formulations potentially needed for the reversal of 
overdoses from potent synthetic opioids (e.g. fentanyl and its 
analogues). Last, ventilator support given as rescue breath-
ing is the cornerstone of opioid-induced respiratory failure.
As stated above, there are basically no safety data on the 
approved products. Pharmacovigilance may answer some of 
the important questions related to the new products. There is 
an urgent need for high-quality randomised comparisons of 
IM vs. IN naloxone administration in overdose. Moreover, 
observational studies independent of industry examining the 
efficacy of the new potent nasal naloxone sprays in overdose 
are warranted. Any consideration of significantly higher ini-
tial doses (than those that worked in the past) should be 
based not on anecdotes but on hard facts.
7  Reviewing the Effectiveness of Take Home 
Naloxone: Application of the Bradford‑Hill 
Criteria
Twenty years after the 1996 BMJ editorial in which the 
notion of THN was first mooted [57], it remained unclear 
whether THN programmes would reduce the rate of opioid 
overdose deaths. The absence of published data from ran-
domised controlled trials meant that uncertainty regarding 
the potential public health benefit of THN programmes per-
sisted, leading to implementation delays and lack of politi-
cal support in many jurisdictions. A small meta-analysis 
[138] had found a significantly increased odds of recovery 
from overdose for naloxone administration by bystanders 
compared with no naloxone administration (odds ratio 
8.58, 95% confidence interval 3.90–13.25), but this analy-
sis was only based on nine studies and 66 overdose events, 
and hence likely not representative of the majority of THN 
programmes.
To address this evaluation gap, a systematic review [139] 
was carried out to assess the effectiveness of THN, in terms 
of impact of opioid overdose mortality. Because of a lack of 
randomised controlled trials and a wide range in the meth-
odological quality of the research studies, a meta-analysis 
was dismissed in favour of an analysis using the Bradford 
Hill [140] criteria: [1] Strength of the Association, [2] Con-
sistency, [3] Specificity, [4] Temporality, [5] Biological 
Gradient, [6] Plausibility, [7] Coherence, [8] Experiment 
and [9] Analogy.
Based on their analysis, the authors [139] concluded that 
THN programmes lead to improved survival rates among 
programme participants and to reduced overdose mortality 
rates in the community. A later publication, which also based 
its analysis on the Bradford Hill criteria, reached a close-to-
identical conclusion [141].
8  Barriers to Wider Implementation
Successful implementation of THN would result in wide-
spread acceptability and availability of the intervention, 
such that it is accessed by relevant target populations and 
embedded in usual practice in drug treatment and main-
stream health services. A number of papers have explored 
legal [142] and workforce [143, 144] barriers. These have 
been country and region specific. To date, there has not been 
a consolidated analysis of barriers to effective THN imple-
mentation. The first reason is that there is not a singular 
model of THN. The second reason is that a comprehensive 
analysis of implementation barriers requires a conceptual 
framework.
For the purposes of the analysis here, we refer to two 
broad types of models of THN implementation. Peer-led 
(PL) models were initially developed by and for PWUO, to 
provide training and supply naloxone directly to people who 
are likely to witness overdoses [138, 145–147]. These PL 
models are provided through organisations oriented to the 
needs of PWUO. In contrast, mainstream healthcare prac-
titioner (MHCP) models harness medical services (doctors 
and pharmacies) to supply naloxone to patients and carers. 
Despite some overlap, they are very different approaches, 
involve different types of negotiation, and bring different 
advantages and disadvantages. They also vary in their suit-
ability for different countries or states at different points in 
time.
Here, we use Greenhalgh et al.’s conceptual framework 
[148] to consider determinants of THN implementation 
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across the two models. Based on the framework, achieving 
scaled-up implementation of THN involves considerations 
regarding the features of the innovation (such as efficacy, 
product, compatibility); the outer context (including socio-
political climate, legal regime and policies, incentives and 
mandates); the system antecedents and readiness for change 
(such as organisational structures); the role of individual 
adopters (such as match with needs, motivation); communi-
cation and influence (such as social networks, champions); 
and the implementation process itself (formalised decision 
making, logistics and costs). This framework is not a pre-
scription for successful diffusion of innovation, but an aid 
to considering the multiple aspects, behaviours, and deter-
minants and their interactions.
8.1  Innovation Itself
Several determinants of successful implementation reside 
in the innovation itself, including the nature of the nalox-
one product. The injectable naloxone products present some 
barriers, with concerns including those relating to needle-
stick injuries [76]. The newer IN formulations represent a 
significant advance in the product formulation and address 
previous concerns about IN bioavailability [11, 92, 149]. 
With recent reports of synthetic fentanyl not being respon-
sive to usual doses of naloxone [150], we should also not be 
complacent about efficacy issues (please consult the THN 
safety discussion, Sect. 6.7)
The prescription status of THN is a significant feature 
impacting on implementation. Prescription products almost 
always require medical scripting and pharmacy dispens-
ing and a trained, resourced and supported workforce (see 
below). Availability via OTC [151] and standing orders 
[152] address some barriers but not without other barriers 
arising such as workforce, the potential cost to patients (in 
some countries) and access [152, 153]. Currently, there are 
also major issues with stock and supply in many countries 
including the USA, UK and Australia [153, 154].
Implementation success is also subject to the compatibil-
ity of the intervention with the groups delivering it. In the-
ory, THN is highly compatible with the values, norms, and 
needs of peers and carers (saving friends and loved ones), 
as well as healthcare professionals (reduced mortality). Yet 
for both PL and MHCP, there may be some incompatibility 
with goals. For the PL models, a recently published quali-
tative study of the views of PWUO highlighted the com-
plex judgement about when to use naloxone given concern 
about “ruining someone’s high” (p. 34) [155]. There was 
no consensus on defining the line between a good high and 
an overdose [155]. For MHCP, there are concerns that pro-
viding such a life-saving intervention may encourage less 
safety in drug use [156–158]. Heavey et al. [155] found that 
some participants reported that naloxone access changed the 
quantity and frequency of use: “chase a bigger high” (page 
32; but see also [159]). A recent working paper [156] that 
suggested a ‘moral hazard’ problem with THN provoked 
a furor, although most commentators consider the analy-
sis weak and conclude that the evident logic and benefit of 
THN remain clear [160, 161]. Nevertheless, the intensity 
of debate from this paper reveals that there is more work to 
do in ensuring that THN is seen as compatible with health 
caring roles, as well as managing the perceived risks associ-
ated with THN.
8.2  Outer Context
The second domain of implementation in Greenhalgh et al.’s 
framework is the “outer context” including the socio-polit-
ical climate and policy context. The legal frameworks are 
important in introducing and sustaining THN, including 
laws concerned with indemnity for consumers (from being 
charged with offence), and medical personnel (prescribers/
dispensers) immunity from being sued [142, 162–165]. The 
legal barriers differ between PL and MHCP models. The 
extent to which these legal regimes are directly associated 
with increased uptake has yet to be empirically demonstrated 
[166]. Nonetheless, a conducive legal environment is a pre-
requisite for widespread implementation.
A key barrier within the outer context domain is the broad 
stigma and marginalisation of people who use opioids. The 
general community largely has negative attitudes towards 
PWUO [167, 168], and this is compounded by internalised 
stigma [169].
The outer context in the Greenhalgh et al. framework also 
covers system incentives and mandates. These are the for-
malised policies and procedures that regulate and support 
THN programmes. While international documents refer-
ence the importance of THN [9, 170], beyond these, there 
appear to be few formal organisational incentives, directives 
and mandates in place currently. Mandatory co-prescribing 
of naloxone with opioid prescriptions has been proposed 
to address prescription opioid overdoses, and pilot studies 
have tested this in clinical practice, finding it feasible and 
associated with reduced opioid-related adverse events [171].
8.3  System Antecedents and Readiness for Change
In Greenhalgh et al.’s framework, both system antecedents 
and readiness for change are key determinants of implemen-
tation success. A receptive context for change, with lead-
ership and vision by the medical profession and by drug 
user organisations is a pre-requisite for success. Drug user 
organisations are often under-resourced, and specific fund-
ing to provide PL programmes is required. For the MHCP 
model, the systems and structures for prescribing and dis-
pensing naloxone are certainly well developed. However, 
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barriers remain with respect to adoption by the workforce 
(see Sect. 8.4).
8.4  Adopters
There are three essential groups of “adopters” whose needs, 
motivations, values and goals need to align with the inter-
vention to ensure effective widespread availability of THN: 
people with an opioid-overdose risk; peers and carers; and 
healthcare professionals. One barrier for potential adop-
ters is stigma, including negative perceptions of PWUO by 
healthcare providers [172], as well as the stigma of being 
identified as a person who may use drugs [173]. Stigma 
reduction programmes targeted at the potential adopters 
(as well as the general community, see Sect. 8.3) may be 
required [174–176]. The universal supply of naloxone to all 
with a risk of opioid overdose as part of standard care (and 
with a patient ‘opt out’ model [177]) has been proposed to 
address stigma, and also address clinicians’ duty of care 
where overdose risk is identified. The cost effectiveness of 
universal supply models is unknown.
There are also significant barriers in relation to knowl-
edge and skills including the need for education and training 
of potential healthcare providers to enable adoption of THN 
in the MHCP model [144, 178]. While PWUO often have 
considerable knowledge of overdose signs and symptoms, 
knowledge gaps exist amongst different populations with 
opioid-overdose risk [155, 173, 179].
8.5  Implementation Processes
The process of implementation presents two key barriers here 
for THN: the workflow logistics and cost. Healthcare profes-
sionals have limited time, and THN needs to be incorporated 
into their workflow, including how to get the THN kit to the 
patient and the timing of this [152]. There is an opportunity 
cost for time-pressured healthcare professionals, where train-
ing patients on naloxone use may leave less time for other 
needs. For general medical practitioners and pharmacists, this 
can be compounded by the systems that pay for their time. 
For PL models, significant resources are required to deliver 
training programmes, which peer organisations may not have.
A further substantial implementation barrier is cost, which 
relates to the medication itself and who is expected to pay. As 
a prescription medicine, the costs may be covered centrally as 
part of regular treatment, or subsidised through private health 
insurance plans, Medicare and Medicaid [142] and/or through 
grants to harm reduction programmes to purchase THN and 
then provide it free of charge to clients. In Australia, a script 
for THN will be affordable to a concession card holder, but 
OTC (i.e. not subsidised) supply significantly increases the 
cost to the consumer [153]. Thus, while new supply routes 
(such as OTC) and formulations (IN) reduce some barriers, 
they simultaneously present other barriers (in these cases, the 
cost).
8.6  Communication and Influence
At present, THN largely remains an isolated initiative led by 
individual champions, harm reduction advocates or health pro-
fessionals experienced in drug dependence. For it to become 
a mainstay of usual care, much wider dissemination and dif-
fusion of the technology need to take place. Here, the system 
variables discussed earlier become most important: wide-
spread stigma against PWUO, the lack of systematic endorse-
ment across all settings and the absence of wide access (such 
as OTC) that can be provided at low cost.
8.7  Understanding Barriers and Developing 
Integrated Responses
Across the analysis conducted here using one conceptual 
implementation framework, it becomes clear that THN imple-
mentation has barriers related to the intervention itself (nota-
bly the product and its prescription status), the outer context 
(stigma and a lack of formalised policies and procedures), the 
adopters (in particular attitudes, knowledge and skills of adop-
ters), and in the practicalities of implementation, especially 
the cost and the logistics. These determine the extent of THN 
diffusion such that it becomes a part of regular practice.
9  Conclusions
9.1  Potentially Transformative Public Health 
Intervention
Naloxone is a well-established emergency medicine for 
the treatment of life-threatening heroin/opioid overdose. In 
recent years, with interest in technology transfer, the concept 
of ‘THN’ has evolved, comprising pre-provision of the sup-
ply of naloxone to individuals who may be in the position to 
intervene and provide essential interim care whilst awaiting 
the arrival of an ambulance.
9.2  Better Naloxone Products Required for More 
Effective Take‑Home Naloxone
New naloxone products (auto-injector and nasal spray) have 
been developed in the last few years that have good bio-
availability, can provide therapeutic doses in a single step, 
and hence are suitable for use by lay responders and other 
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non-medical personnel. Four concentrated nasal spray prod-
ucts have now reached the stage of regulatory approval,5 
with several already introduced in some countries globally: 
 Narcan® 4 mg (USA, Canada, approved and introduced in 
2016–2017)6,  Nalscue® 1 mg (approved and introduced 
in France in 2017),  Nyxoid®7 2 mg (European Medicines 
Agency approval in 2017, introduced across much of Europe 
from 2018 onwards) and  Ventizolve® 1.4-mg spray (devel-
oped in Norway and approved for 12 European countries in 
June 2018).
9.3  Elephant in the Room: Cost and Affordability
When comparing the different naloxone devices, including 
ampoules and vials as the most basic, there is a clear trade-
off between usability and cost. With all products containing 
the same medication (naloxone), this point is perhaps best 
illustrated with the example of the FDA-approved auto-
injector  (Evzio®). At approximately US$600–4500 per 
unit, the auto-injector is at risk of being considered almost 
irrelevant for community-wide provision. New concentrated 
nasal sprays, if costs are kept low, might be particularly suit-
able for much wider public pre-provision. The cost of twin 
packs of the new approved naloxone nasal sprays varies 
between countries from approximately US$30 (equivalent) 
to several hundred dollars, compared with less than a dollar 
for ampoules vs. several thousand dollars for auto-injectors. 
The affordability of new naloxone products will likely define 
their real-world availability and accessibility for the target 
population.
9.4  Over‑the‑Counter Status
As discussed above (see Sect. 8), re-scheduling of nalox-
one to OTC medication could remove several logistical and 
legal barriers. However, the issue of THN costs overlaps 
with the issue of OTC status as high cost could render the 
product unattainable, even if technically available OTC. By 
analogy, in the prevention of sexually transmitted infections, 
cost is a barrier to condom use [180], and free-of-charge 
condom distribution to target high-risk populations is recom-
mended [181, 182]. A dual implementation model is likely 
optimal for naloxone access: potential OTC sales should best 
be considered as operating alongside free-of-charge THN 
programmes.
9.5  Opioid Overdose Prevention in Low‑ 
and Middle‑Income Countries
The question of the cost of non-injectable naloxone (vs. 
injectable forms of the same medicine) becomes particu-
larly relevant for global health. With support from the 
Global Fund, several countries currently procure naloxone 
ampoules at the low cost of approximately US$0.50 per 
ampoule (0.4 mg/mL). Local non-governmental organisa-
tions typically hand out two take-home ampoules per cli-
ent, i.e. equivalent to a total medicine cost of US$1.00 per 
person. Given the cost disparity between the nasal spray and 
local ampoule supply, the purchase of naloxone nasal spray 
is likely not sustainable for low- and middle-income coun-
tries at present. However, bulk buying and the production 
of generics could lower costs in the long term, as has been 
achieved for second-line antiretroviral therapy for human 
immunodeficiency virus/acquired immune deficiency syn-
drome in low- and middle-income countries, where medica-
tion costs have been dramatically reduced.
9.6  Need for Continued Research
Surprisingly little attention has been paid to study these new 
naloxone products with participants from the relevant tar-
get population of individuals with substance use disorders, 
hence uncertainty remains. Will damage to nasal membranes 
from long-term drug use alter the speed and effectiveness of 
absorption? Are the findings from healthy volunteers gener-
alisable to overdose victims with potentially very low body 
weight, near-universal chronic smoker status or varying 
degrees of hepatic impairment? Is nasal bioavailability of 
naloxone higher under opioid influence? Can dose titration 
be taught effectively? What is a safe starting dose, the dose 
that together with a similar follow-up dose within 3 min that 
reverse most respiratory failures without provoking too much 
withdrawals? Such studies may be challenging to devise and 
conduct, but they would ordinarily be considered necessary 
steps with the development of new interventions with other 
clinical populations. There is also a need for stronger study 
designs to guide further improvements in THN provision.
9.7  Final Remarks
Take-home naloxone has established itself as a major new 
strand of our response to opioid overdose deaths. This has 
required new policies and practices, alongside new naloxone 
formulations and products. These have been developed suc-
cessfully, and continue to be refined for new challenges, new 
6 A 2-mg version of Narcan® was also approved in North America 
but was never introduced in clinical practice—see footnote to Table 3.
7 See footnote to Table 3 for explanation of dose of Nyxoid.
5 A generic version of the 4-mg/0.1-mL Narcan nasal spray by Teva 
Pharmaceuticals also received FDA approval in April 2019 in the US 
but has not yet been introduced; and an application in the US from 
InSys for an 8-mg/0.1-mL naloxone nasal spray was accepted for con-
sideration by FDA in July 2019.
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countries and contexts, and for new opioid drug problems. 
More research is, of course, needed—with stronger research 
designs as well as the need for new products and new meth-
ods of provision; but this new research must be conducted 
alongside the introduction of the best products and prac-
tices that already exist. With a large and growing problem 
of heroin/opioid overdose deaths, we have a responsibility to 
expect the best of science, policy and practice to guide our 
local, national and global responses.
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